On Friday, November 4, 2016, the Antimicrobial Drugs Advisory Committee (AMDAC) narrowly supported, by a vote of 7-Yes to 6-No, with no abstentions, the safety and efficacy of solithromycin capsules and solithromycin for injection, sponsored by Cempra Pharmaceuticals, Inc. (Cempra), for the proposed indication of the treatment of community-acquired bacterial pneumonia (CABP).
See the SAC Tracker report